Protein–Protein Interactions News and Research

RSS

Novel technique could speed up the development of peptide-based drugs against cancer

Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes.

9 Feb 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Systematic study on protein-protein interfaces explain "promiscuous" phenomena of its binding

Interactions between proteins are at the heart of cellular processes, and those interactions depend on the interfaces where the direct physical contact occurs. A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces - and that their structures depend largely on the simple physics of the proteins.

16 Dec 2010

Scripps Research Institute enters agreement with Aileron Therapeutics

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology.

1 Dec 2010

Isogenica enters collaborative agreement with University of Cambridge Professor

Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge.

2 Nov 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

Evotec enters multiple target drug discovery collaboration with Shionogi

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

5 Oct 2010

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

24 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

NIH awards BU $1.6M grant to target protein-protein interactions with synthetic organic drugs

An interdisciplinary team of Boston University professors is launching a project to develop new ways to target protein-protein interactions with synthetic organic drugs. Financed by a four-year $1.6 million grant from the National Institutes of Health, the goal is to develop new approaches for discovering "drug-like" small molecule inhibitors against challenging protein-protein interaction (PPI) interfaces.

27 Jul 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Compugen reports revenues of $125,000 for first-quarter 2010

Compugen Ltd. today reported financial results for the first quarter ending March 31, 2010.

27 Apr 2010

Compugen announces development of PPI Blockers Discovery Platform

Compugen Ltd. announced today the development of its Protein-Protein Interaction Blockers (PPI Blockers) Discovery Platform, designed for the prediction of peptides to block disease associated protein-protein interactions. In a pilot validation run, predicted peptides showed positive results for drug targets in two cancer related pathways of interest to the industry.

23 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Researchers report major step forward in effort to understand and engineer protein structure

Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms. Their study culminated in one of the first successful attempts to take apart a complex biological nanostructure and isolate the rules that govern its natural formation.

12 Apr 2010

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

11 Mar 2010

Boehringer Ingelheim, Priaxon announce collaboration in development of mdm2/p53 inhibitors for cancer

Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions. p53 is a human tumor suppressor protein.

18 Jan 2010

Elusive human protein outsmarted

A team of researchers is being recognized for devising a new way to study a human protein that long has evaded close scrutiny by scientists investigating its role in the communication of important genetic messages inside a cell's nucleus to workhorse molecules found elsewhere.

5 Jan 2010

Publication validates company's structure-based approach for addressing undruggable targets

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects.

28 Dec 2009